ESR1 and breast cancer: Rauscher et al. found that in breast cancer NFE2L3 displays hypermethylation for estrogen receptor (ER)-positive tumors and hypomethylation for ER-negative tumors, and methylation level of its promoter region exhibits an inverse correlation with expression among the cancer samples [34].